Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Walkty
John Embil

Showing results (81-90 of 134) with videos related to

Pageof 14
Sort By:
Antimicrobial Agents and Chemotherapy|October 20, 2020
Identification and Characterization of a Novel FosA7 Member from Fosfomycin-Resistant Escherichia coli Clinical Isolates from Canadian HospitalsKieran A Milner, Denice C Bay, David Alexander, et al.
Journal of Clinical Microbiology|September 8, 2021
Use of Fosfomycin Etest To Determine <i>In Vitro</i> Susceptibility of Clinical Isolates of <i>Enterobacterales</i> Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive CocciJames A Karlowsky, Melanie R Baxter, Alyssa R Golden, et al.
Infection Control and Hospital Epidemiology|February 5, 2008
Vancomycin-resistant enterococci in Canada: results from the Canadian nosocomial infection surveillance program, 1999-2005Marianna Ofner-Agostini, B Lynn Johnston, Andrew E Simor, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2025
Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007-23Philippe Lagacé-Wiens, Laura Mataseje, Melissa McCracken, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2025
Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6 years of the CANWARD study (2018-23)Melissa McCracken, Andrew Walkty, Heather J Adam, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2010
Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolatesAndrew Walkty, David A Boyd, Denise Gravel, et al.
Antimicrobial Agents and Chemotherapy|April 1, 2015
In vitro activity of ceftazidime-avibactam against 338 molecularly characterized gentamicin-nonsusceptible Gram-negative clinical isolates obtained from patients in Canadian hospitalsAndrew J Denisuik, James A Karlowsky, Tyler Denisuik, et al.
Drugs|January 16, 2004
The glycylcyclines: a comparative review with the tetracyclinesGeorge G Zhanel, Kristen Homenuik, Kim Nichol, et al.
Scientific Reports|November 9, 2021
Assessment of cleaning methods on bacterial burden of hospital privacy curtains: a pilot randomized controlled trialKianna Cadogan, Sabrin Bashar, Saul Magnusson, et al.
Antimicrobial Agents and Chemotherapy|May 4, 2011
Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance studyJames A Karlowsky, Philippe R S Lagacé-Wiens, Patricia J Simner, et al.
Pageof 14

Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
Antimicrobial Agents and Chemotherapy|October 20, 2020
Identification and Characterization of a Novel FosA7 Member from Fosfomycin-Resistant Escherichia coli Clinical Isolates from Canadian HospitalsKieran A Milner, Denice C Bay, David Alexander, et al.
Journal of Clinical Microbiology|September 8, 2021
Use of Fosfomycin Etest To Determine <i>In Vitro</i> Susceptibility of Clinical Isolates of <i>Enterobacterales</i> Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive CocciJames A Karlowsky, Melanie R Baxter, Alyssa R Golden, et al.
Infection Control and Hospital Epidemiology|February 5, 2008
Vancomycin-resistant enterococci in Canada: results from the Canadian nosocomial infection surveillance program, 1999-2005Marianna Ofner-Agostini, B Lynn Johnston, Andrew E Simor, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2025
Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007-23Philippe Lagacé-Wiens, Laura Mataseje, Melissa McCracken, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2025
Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6 years of the CANWARD study (2018-23)Melissa McCracken, Andrew Walkty, Heather J Adam, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2010
Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolatesAndrew Walkty, David A Boyd, Denise Gravel, et al.
Antimicrobial Agents and Chemotherapy|April 1, 2015
In vitro activity of ceftazidime-avibactam against 338 molecularly characterized gentamicin-nonsusceptible Gram-negative clinical isolates obtained from patients in Canadian hospitalsAndrew J Denisuik, James A Karlowsky, Tyler Denisuik, et al.
Drugs|January 16, 2004
The glycylcyclines: a comparative review with the tetracyclinesGeorge G Zhanel, Kristen Homenuik, Kim Nichol, et al.
Scientific Reports|November 9, 2021
Assessment of cleaning methods on bacterial burden of hospital privacy curtains: a pilot randomized controlled trialKianna Cadogan, Sabrin Bashar, Saul Magnusson, et al.
Antimicrobial Agents and Chemotherapy|May 4, 2011
Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance studyJames A Karlowsky, Philippe R S Lagacé-Wiens, Patricia J Simner, et al.
Pageof 14